Brief: BridgeBio Pharma Says Acoramidis Reduces CVM Or CVH Risk By 49% Through Month 30
28/09/2025 16:18
Sept 28 (Reuters) - BridgeBio Pharma Inc BBIO.O: ACORAMIDIS BEGINS TO REDUCE CUMULATIVE CARDIOVASCULAR OUTCOMES WITHIN THE FIRST MONTH OF TREATMENT IN PATIENTS WITH ATTR-CM BRIDGEBIO PHARMA INC - ACORAMIDIS REDUCES CVM OR CVH RISK BY 49% THROUGH MONTH 30 Source text: ID:nGNX4yHZDw Further company coverage: BBIO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BridgeBio Pharma
See all newsU.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
BridgeBio rises on FDA priority review for dwarfism drug
Brief: Bridgebio Announces FDA Acceptance And Priority Review Of NDA For Oral Infigratinib For Children With Achondroplasia
Brief: Bbp-418 Demonstrates Potential To Be Disease Modifying Therapy, Restoring Cardiac And Disease Markers To Unaffected Levels